Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #2154299

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
USD
10,548,000 USD
10,548,000 USD
USD
USD
USD
USD
13,674,000 USD
USD
13,674,000 USD
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
9,069,000 USD
5,463,000 USD
Adjustments for decrease (increase) in inventories
14,434,000 USD
15,016,000 USD
Adjustments for share-based payments
9,251,000 USD
6,392,000 USD
Adjustments for fair value losses (gains)
930,000 USD
1,185,000 USD
Adjustments for undistributed profits of associates
289,000 USD
1,083,000 USD
Other adjustments for non-cash items
1,079,000 USD
1,576,000 USD
Adjustments for losses (gains) on disposal of non-current assets
21,279,000 USD
USD
Interest received, classified as operating activities
2,883,000 USD
85,000 USD
Income taxes paid (refund), classified as operating activities
655,000 USD
1,235,000 USD
Cash flows from (used in) operating activities
17,302,000 USD
22,458,000 USD
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
1,437,000 USD
1,376,000 USD
Proceeds from sales of intangible assets, classified as investing activities
21,279,000 USD
USD
Purchase of intangible assets, classified as investing activities
27,000 USD
601,000 USD
Cash flows from (used in) investing activities
129,388,000 USD
5,323,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing other equity instruments
8,133,000 USD
2,281,000 USD
Payments of lease liabilities, classified as financing activities
5,126,000 USD
3,311,000 USD
Interest paid, classified as financing activities
4,046,000 USD
3,952,000 USD
Cash flows from (used in) financing activities
1,039,000 USD
4,982,000 USD
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
147,729,000 USD
22,799,000 USD
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
2,128,000 USD
7,381,000 USD
Cash and cash equivalents
61,741,000 USD
207,342,000 USD
191,924,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.